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Idiopathic inflammatory myopathies involve skeletal muscles and can be associated with interstitial lung 
disease and/or heart dysfunction, which may reduce exercise capacity. We aimed to clarify cardiopulmonary 
factors affecting the 6-minute walk distance in patients who were able to walk without leg pain or fatigue. 
Twenty-three patients with inactive adult idiopathic inflammatory myopathies, and 18 age- and gender-
matched healthy controls were evaluated for hemodynamic responses using noninvasive impedance 
cardiography during the 6-minute walk test. The patients were also examined by the pulmonary function 
test for forced vital capacity and diffusing capacity for carbon monoxide (DLCO), and by echocardiography 
for left ventricular ejection fraction. Interstitial lung disease was diagnosed in 19 patients using high-
resolution computed tomography. There was no difference in 6-minute walk distance or cardiac output after 
walking between the patients and healthy controls. However, stroke volume during the 6-minute walk test 
was significantly lower in the patients than in healthy controls, suggesting malfunction in the heart. 
Moreover, the increased heart rate matched the cardiac output. Single regression analysis demonstrated a 
correlation between 6-minute walk distance and stroke volume, cardiac output and DLCO, but not left 
ventricular ejection fraction. Furthermore, based on the stepwise regression analysis, DLCO and cardiac 
output after walking affect the 6-minute walk distance. In conclusion, impaired DLCO due to interstitial 
lung disease was suggested to be a fundamental parameter affecting exercise capacity, in addition to heart 
involvement, in patients with idiopathic inflammatory myopathies. 
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Interstitial lung disease is a common extra-muscular complication of idiopathic inflammatory myopathies, 
and low diffusing capacity for carbon monoxide (DLCO) is known to increase the risk of mortality [1, 2]. 
A recent study demonstrated that recovery of skeletal muscle strength and reduced creatine kinase levels 
by medication for idiopathic inflammatory myopathies may improve forced vital capacity (FVC) due to 
muscular strength reinforcement; however, DLCO and interstitial infiltrates on CT were not ameliorated in 
most cases [3]. In general, distance during the 6-minute walk test (6MWT) correlates with FVC and DLCO 
in patients with idiopathic pulmonary fibrosis [4]. Therefore, we hypothesized that accompanying 
interstitial lung disease may be a factor affecting exercise capacity in patients with idiopathic inflammatory 
myopathies, and examined which pulmonary function parameters affect exercise capacity. 
Heart involvement in idiopathic inflammatory myopathies was also detected by cardiac magnetic resonance 
tomography [5] or echocardiography [6], and these findings may lead to therapeutic treatment for the cause 
of morbidity [7]. An increased risk of myocardial infarction or conduction abnormalities was reported in 
patients with idiopathic inflammatory myopathies [8]. Moreover, left ventricular diastolic dysfunction [6] 
and reduced left ventricular ejection fractions (EF) [5] were observed in patients regardless of the presence 
of myalgia, paresis, and exhaustion. Few studies have demonstrated the relationship between cardiac 
functions and exercise capacity in patients with idiopathic inflammatory myopathies. It may be difficult to 
clarify cardiac parameters likely associated with exercise capacity using conventional echocardiography, 
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however, when cardiac impairment was assessed by global longitudinal strain measurement, subclinical 
heart disease was found in up to 50% of patients [9]. 
Referring to other estimates for cardiac parameters, recent studies have demonstrated that impedance 
cardiography with real-time monitoring can noninvasively evaluate hemodynamic responses during the 
6MWT (10, 11). Pulmonary hypertension patients with a normal ejection fraction had a lower stroke volume 
(SV) and cardiac index (CI) compared with healthy controls during walking [10], and patients with chronic 
obstructive disease exhibited slower responses to increasing cardiac output (CO) [11]. Moreover, the 
maximal CO in patients with pulmonary hypertension was observed during the 6MWT by the inert gas 
rebreathing method [12]. Thus, these noninvasive methods may be available for evaluation of 
hemodynamic responses during walking to examine the relation between exercise capacity and heart 
involvement in patients with idiopathic inflammatory myopathies. 
In the present study, we investigated lung and cardiac function parameters related to limited exercise 
capacity in patients with idiopathic inflammatory myopathies. For cardiac function, we compared 
measurements obtained from patients and age- and gender-matched healthy controls during the 6MWT 
using noninvasive impedance cardiography. 
 
Methods 
Patients receiving medication for idiopathic inflammatory myopathies were recruited among patients 
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referred to the Rehabilitation Division of Kanazawa University Hospital between November 2014 and 
September 2017 for consultation on further treatments. They received muscular training, pulmonary 
rehabilitation, and education about activities of daily living. Exclusion criteria for this study were juvenile 
dermatomyositis, overlap with other connective tissue diseases, muscle weakness in the extremities of less 
than 4 on manual muscle testing, leg discomfort or pain during the 6MWT, and active myositis, i.e., period 
of increased serum creatine kinase. In total, 23 patients were assigned to this study (Table 1). On 
autoantibody analysis, 7 had anti-ARS (anti-Jo-1, PL-7, EJ, and OJ), 10 had anti-MDA5, 2 had anti-SRP, 3 
had anti-TIF1-γ, and 1 was unknown. Interstitial lung disease was diagnosed in 19 patients by specialists 
of respiratory medicine using high-resolution computed tomography. The study was approved by the human 
ethics committee of Kanazawa University, conforming to the provisions of the Declaration of Helsinki. 
Written informed consent for the study was obtained from all patients and 18 healthy controls before the 
performance of the 6MWT. 
Hemodynamic responses during the 6MWT were measured using the PhysioFlow Q-Link (Manatec 
Biomedical, France), which weighed 200 g and was wearable. Six disposable electrodes (BlueSensor SP, 
Ambu, Denmark) connecting to the equipment were placed around the chest for impedance cardiography, 
as previously described [10]. The 6MWT was performed following the Guidelines of the American 
Thoracic Society in a 30-m corridor [13]. SV, heart rate, CO, and CI were recorded at rest for autocalibration 
for 30 sec before the 6MWT. Subsequently, the data were automatically averaged every 10 sec during the 
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6MWT, and values at 6 minutes of walking were collected for analyses (Figure 1). 
The clinical data of percentages of predicted FVC and DLCO (FVC% and DLCO%) from pulmonary 
function tests, and left ventricular EF from echocardiography was collected by reviewing the medical 
records of the patients. These evaluations were not performed for healthy controls, as we expected the 
values to be normal. 
 
Statistics 
Clinical characteristics were compared between the patients and healthy controls using the t test for 
numerical data, and chi-square test for gender distribution. The relation between SV at rest and that at 6 
minutes was examined using Pearson correlation coefficients for all subjects. Single and stepwise 
regression analyses were performed for 6MWT distance and FVC%, DLCO%, EF, SV, and CO at rest and 




There was no difference in gender distribution, age, or anthropometric measurements between patients and 
healthy controls. The mean DLCO% was low at 61.8% in patients, and seemed to be poorer than the mean 
FVC%, which was 95.4% (Table 1). The EF in patients was not impaired at 68.4 ± 8.2%, mean ± SD. The 
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SV, CO, and CI at rest, and SV at 6 minutes were significantly lower in patients than in healthy controls. 
Patient heart rates were high, but there was no significant difference between patients and healthy controls. 
The CO at 6 minutes was lower and 6MWT distance was shorter for patients, but neither difference was 
significance. A strong correlation between SV at rest and that at 6 minutes was observed in all subjects (r = 
0.87, p < 0.0001) (Figure 2). 
In the healthy controls, the 6MWT distance was correlated with CO at 6 minutes, but not with SV (Table 
2). On the other hand, single regression analysis revealed a significant correlation between 6MWT distance, 
and DLCO% and SV at rest and at 6 minutes, and CO at 6 minutes in the patients. There was no correlation 
between 6MWT distance and EF. A best fit model for 6MWT distance in patients with DLCO% and CO at 
6 minutes was created by stepwise regression analysis (r2 = 0.61, p = 0.02). 
 
Discussion 
This is the first study to evaluate exercise capacity in patients with idiopathic inflammatory myopathies in 
relation to lung and heart function parameters. EF is a widely used parameter representing cardiac function 
[14], and if patients with idiopathic inflammatory myopathies have reduced EF (< 60%), late gadolinium 
enhancement by cardiac magnetic resonance tomography is observed [5]. In this study, EF was normal in 
patients and there was no correlation with 6MWT distance, whereas the SV was significantly lower than 
that in healthy controls. Therefore, EF was unable to be used to estimate the exercise capacity in our cohort. 
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SV at 6 minutes in healthy controls was not correlated with 6MWT distance. It was previously reported that 
in healthy subjects, heart rate response contributed to CO or oxygen uptake rather than the SV response 
during exercise [15]. Additionally, varying response patterns in SV to exercise were previously observed in 
healthy subjects, but the mechanism was not clarified [16]. On the other hand, in this study, SV at rest was 
highly correlated with SV at 6 minutes in all subjects, and little variation in SV was noted in response to 
the 6MWT. Therefore, the significant deterioration in SV at rest in patients implied proportionally low SV 
during walking, which affected 6MWT distance. Impaired SV at rest or at 6 minutes suggests malfunction 
in the heart not detected by EF.  
CO is known to be correlated with oxygen uptake during exercise in healthy subjects [17], and CO at 6 
minutes was also correlated with 6MWT distance in healthy controls and patients on single regression 
analysis. As CO and CI at 6 minutes were compensated for by the increased heart rate despite lower SV in 
patients, the difference in 6MWT distance between patients and healthy controls was unclear. However, 
stepwise regression analysis supported the relationship between 6MWT distance and CO at 6 minutes, but 
not SV, in patients, which suggests that CO compensation during exercise influences exercise capacity. 
The other variable affecting 6MWT distance was DLCO% according to the fit model for 6MWT distance 
in patients, and this result was considered to confirm our hypothesis that accompanying interstitial lung 
disease affects the exercise capacity in patients. As interstitial lung disease was diagnosed in 82% (19 of 23 
patients) of the patients in this study, it may be the principal manifestation affecting exercise capacity in 
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our cohort. A significant relationship between DLCO and exercise capacity was previously confirmed in 
patients with idiopathic pulmonary fibrosis [4, 18]. In addition, DLCO better represented impairment of 
pulmonary gas exchange than other parameters such as PaO2, alveolar-arterial oxygen pressure difference, 
and pulmonary capillary blood volume [19, 20]. 
FVC is another parameter on the pulmonary function test, but it was not related with 6MWT distance in the 
patients. For this reason, the value of FVC%, which had a mean value of 95.4%, was normal compared 
with DLCO%, which was 61.8%. As the patients had inactive myositis, FVC may have been recovered [3] 
when we evaluated them. If the patients were more impaired, the exercise capacity may have been affected, 
as reported for patients with idiopathic pulmonary fibrosis [4]. 
Regarding other factors for exercise capacity, a previous study failed to find a correlation between serum 
creatine kinase and peak oxygen uptake or peak isometric torque in patients with inactive idiopathic 
inflammatory myopathies [21]. In addition, glucocorticoids and other medications may cause muscle 
weakness that lasts for several weeks or years [22]. Thus, many factors should be taken into consideration 
when evaluating the exercise capacity in patients with idiopathic inflammatory myopathies. However, we 
set the exclusion criteria for this study as muscle weakness in the extremities of less than 4 on manual 
muscle testing and leg discomfort or pain during the 6MWT to clarify the effects of cardiopulmonary 
functions on exercise capacity by excluding muscle factors. If all factors, such as muscle fatigue during 
active myositis, were included in the analysis, a different result may have been obtained. 
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The limitation of this study was the extraction condition of patients mentioned above. These results cannot 
be extended to patients who are unable to walk sufficiently. Our aim was to clarify the effects of lung and 
heart involvement on exercise capacity in patients with a certain condition. We demonstrated the influence 
of pulmonary factors in addition to cardiac factors on exercise capacity in these patients, and pulmonary 
rehabilitation is recommended to improve their functional status and quality of life [23]. However, 
idiopathic inflammatory myopathies generally involve skeletal muscle, and the relationship between 
muscle symptoms and exercise capacity should be examined in the future. 
 
Conclusion 
Among the manifestations of idiopathic inflammatory myopathies, we evaluated deterioration in the lung 
and the heart in relation to exercise capacity using the 6MWT. The SV during the 6MWT was impaired in 
patients compared with in healthy controls, and the parameters influencing 6MWT distance were CO at 6 
minutes and DLCO%. Interstitial lung disease may be a factor limiting exercise capacity in patients with 
idiopathic inflammatory myopathies who can walk. 
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Table 1. Characteristics of subjects 
 Healthy controls 
 (n = 18) 
Myopathy patients 
(n = 23) 
P 
Gender (f/m) 12/6 13/10 0.51 
Age (year) 59 ± 12 57 ± 13 0.63 
Height (cm) 161 ± 10 161 ± 7 0.87 
Weight (kg) 57 ± 9 56 ± 9 0.68 
Body-Mass Index 22 ± 2 22 ± 4 0.63 
6MWT distance (meters) 539 ± 80 498 ± 97 0.15 
FVC (% prediction) - 95.4 ± 22.3  
DLCO (% prediction) - 61.8 ± 17.2  
EF (%) - 68.4 ± 8.2  
At rest    
Stroke volume (mL) 71.6 ± 12.4 55.2 ± 16.9 0.0009 
Heart rate (beats/min) 78 ± 13 86 ± 13 0.051 
Cardiac output (L) 5.6 ± 1.2 4.6 ± 1.4 0.03 
Cardiac index 3.5 ± 0.7 2.9 ± 0.8 0.02 
At 6 min of 6MWT    
Stroke volume (mL) 106.6 ± 13.7 79.4 ± 27.9 0.0003 
Heart rate (beats/min) 122 ± 23 134 ± 28 0.14 
Cardiac output (L) 13.0 ± 2.9 10.7 ± 4.6 0.06 
Cardiac index 8.2 ± 1.6 6.7 ± 2.9 0.054 
Values are mean ± SD. 6MWT; 6-min walk test, FVC; forced vital capacity, DLCO; diffusing capacity for 
carbon monoxide, EF; ejection fraction. FVC, DLCO, and EF were not measured in healthy controls. 
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Table 2. Correlation between 6-minute walk distance and cardiopulmonary parameters using single 
regression analysis 
 Healthy controls Myopathy patients 
Parameters R2 P R2 P 
FVC (% prediction) - - 0.14 0.11 
DLCO (% prediction) - - 0.33 0.03 
EF (%) - - 0.0002 0.96 
Stroke volume (mL), at rest 0.02 0.57 0.23 0.02 
Cardiac output (L), at rest < 0.01 1.00 0.15 0.07 
Stroke volume (mL), at 6 min on 6MWT < 0.01 0.80 0.40 0.001 
Cardiac output (L), at 6 min on 6MWT 0.39 0.006 0.40 0.001 
6MWT; 6-min walk test, FVC; forced vital capacity, DLCO; diffusing capacity for carbon monoxide, EF; 
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Figure 1. Hemodynamic responses recorded by noninvasive impedance cardiography during the 6-minute 
walk test (6MWT) in a patient. 
 
Figure 2. Relationship between stroke volume (SV) at rest and at 6 minutes during the 6-minute walk test. 
Open circles represent healthy controls and closed circles represent patients with idiopathic inflammatory 
myopathies. R = 0.87, p < 0.0001. 
 
